Amgen (AMGN) Cyclically Adjusted Revenue per Share: $54.17 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMGN Amgen Inc AMGN
80 GF Score
Price $393.10
GF Value $353.90
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Amgen Cyclically Adjusted Revenue per Share?

Amgen AMGN +4.48% 80 Cyclically Adjusted Revenue per Share is $54.17 as of Mar. 2026. GuruFocus rates AMGN with a GF Score™ of 80/100 and a GF Value™ of $353.90 (Modestly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Amgen's adjusted revenue per share for the three months ended in Mar. 2026 was $15.842. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $54.17 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Amgen's average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Amgen was 23.00% per year. The lowest was 8.70% per year. And the median was 14.20% per year.

As of today (2026-07-28), Amgen's current stock price is $393.10. Amgen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $54.17. Amgen's Cyclically Adjusted PS Ratio of today is 7.26.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amgen was 8.61. The lowest was 5.09. And the median was 6.91.


Amgen  (NAS:AMGN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Amgen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=393.10/54.17
=7.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amgen was 8.61. The lowest was 5.09. And the median was 6.91.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Amgen Cyclically Adjusted Revenue per Share Related Terms


Amgen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Amgen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cyclically Adjusted Revenue per Share Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.47 40.90 44.33 48.35 52.59

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.61 50.79 51.88 52.59 54.17

AMGN vs GILD, PFE, BMY: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PS Ratio falls into.


AMGN
80GF Score
Amgen Inc AMGN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=15.842/330.2130*330.2130
=15.842

Current CPI (Mar. 2026) = 330.2130.

Amgen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 7.524 241.018 10.308
201609 7.717 241.428 10.555
201612 8.039 241.432 10.995
201703 7.374 243.801 9.988
201706 7.873 244.955 10.613
201709 7.876 246.819 10.537
201712 7.992 246.524 10.705
201803 7.812 249.554 10.337
201806 9.180 251.989 12.030
201809 9.097 252.439 11.900
201812 9.719 251.233 12.774
201903 8.877 254.202 11.531
201906 9.625 256.143 12.408
201909 9.530 256.759 12.256
201912 10.380 256.974 13.338
202003 10.372 258.115 13.269
202006 10.483 257.797 13.428
202009 10.905 260.280 13.835
202012 11.360 260.474 14.402
202103 10.157 264.877 12.662
202106 11.330 271.696 13.770
202109 11.765 274.310 14.163
202112 12.138 278.802 14.376
202203 11.321 287.504 13.003
202206 12.279 296.311 13.684
202209 12.364 296.808 13.756
202212 12.712 296.797 14.143
202303 11.348 301.836 12.415
202306 13.009 305.109 14.079
202309 12.831 307.789 13.766
202312 15.234 306.746 16.399
202403 13.894 312.332 14.689
202406 15.505 314.175 16.296
202409 15.688 315.301 16.430
202412 16.795 315.605 17.572
202503 15.063 319.799 15.554
202506 16.967 322.561 17.370
202509 17.633 324.800 17.927
202512 18.203 324.054 18.549
202603 15.842 330.213 15.842

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $54.17 mean?
Amgen (AMGN) has a Cyclically Adjusted Revenue per Share of $54.17 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amgen and its competitors.
Is Amgen's Cyclically Adjusted Revenue per Share too high?
Amgen's current Cyclically Adjusted Revenue per Share is $54.17. Overall, Amgen has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Cyclically Adjusted Revenue per Share compare to GILD and PFE?
Amgen's Cyclically Adjusted Revenue per Share of $54.17 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amgen and its competitors. Amgen's current Cyclically Adjusted Revenue per Share is $54.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (AMGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $353.90, compared to a current price of $393.10 — trading 11.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $54.17. Amgen's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Amgen (AMGN), the current Cyclically Adjusted Revenue per Share is $54.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (AMGN) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of $393.10 is trading 11.1% above its estimated GF Value™ of $353.90. GuruFocus considers Amgen to be Modestly Overvalued.

Key valuation signals for AMGN:

  • Cyclically Adjusted Revenue per Share: $54.17
  • GF Value™: $353.90 vs. price of $393.10 (11.1% above fair value)
  • GF Score™: 80/100 with 9 warning signs

No single metric tells the full story. See the AMGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
80GF Score

Get the complete analysis for AMGN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$393.10
Price
$353.90
GF Value